Trending...
- Mercy Street to Host the Largest Opening Day Event in the Organization's 20 Year History
- Aquia Inc. Joins the AWS Partner Network and the AWS Public Sector Partner Program
- Orchard Audio's New PecanPi®+ DAC and Streamer Feature AKM's Latest Flagship Chips
SAN JOSE, Calif. - PRDelivery -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on PR Delivery
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on PR Delivery
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on PR Delivery
- 2023 National Farmworker Awareness Week
- Orbex Introduces Double Profits for New Traders
- Quotehunt.co.uk: Revolutionising the UK B2B Market with Comprehensive Comparison Services for Small Businesses
- Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC , a partner of Veterans for Trump
- 2023 Employee Handbook Templates Now Available
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on PR Delivery
- Mercy Street to Host the Largest Opening Day Event in the Organization's 20 Year History
- The Nashville International Chopin Piano Competition Announces the Alexei Sultanov Memorial Discovery Prize
- Kobie Voted a Top Workplace USA
- Aquia Inc. Joins the AWS Partner Network and the AWS Public Sector Partner Program
- Perfect Body Laser and Aesthetics ® Offers Tetra CoolPeel Co2 Laser Skin Resurfacing
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on PR Delivery
- Expert tip: Private Jet Engine Maintenance Program - Pros and Cons for Preowned Jet Buyers
- Gaming and entertainment company Spinrack Corporation, appoints Jesse Norton as Chief Marketing Officer
- .Store Domains launches Elevate.store – a free-to-use platform for online sellers with deals on business tools
- GP GLOBAL GROUP Secures $18M Sale of Shoppes at 41st Street Retail Plaza in Doral, Florida, with $11.5M CMBS Loan Assumption
- HLN's Immunization Calculation Engine (ICE) is continually updated to support new COVID-19 recommendations
- Rewilding Ireland with Lord Dunsany and IrishTrees
- The Tokyo Rebels Announces the Release of Their Groundbreaking Whitepaper
- Armadillos with Benefits™ - PicPocket-Labs, Inc. details its plans/roadmap at SxSW for combining "location-based NFTs" and loyalty programs
- Microsoft-Backed HRtech Startup ZingHR Invests In SaaS Startup LokiBots
- World Sleep Day, why do we celebrate?
- HGR Alcohol Detox Centers in San Diego Accepts Most Health Insurances
- ShopCHARLI.com Launches Online Store With a Hot New Spring Collection that Doesn't Miss
- Congressman Mark Alford endorsed by Veterans for Trump on his 2024 re-election
- February 2023 Financial Market Review
- Bicycle Sunshade Expands Product Line with Two New Colors
- The Past Reflects A Future - Daniel Imperato 2024 Is Back Again. Which Party?
- Fridge Art Fair New York City May 2023
- Empowering SMEs: Innervation's Supply Chain Finance Solutions for Diverse Business Growth
- AdvisorVault Partners With Compliant Workspace to Help FINRA Firms Achieve 17a-4 Compliance on Microsoft 365
- The New Real Estate "Just Looking" Program Is A Big Hit With Atlanta Area Residents!